Caribou Biosciences : Regulation FD Presentation - Form 8-K
Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or... | March 29, 2023